Once a staple in American households, direct to consumer companies like Tupperware and Avon are seeing significant shake ups after filing for bankruptcy.

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

In today’s health-conscious world, manufacturers across various sectors are reshaping their strategies to cater to evolving ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Discounting plays a critical role, but its not the only way to stand out online. Here's how seven leading brands are ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

French pharma giant Sanofi is selling off its consumer healthcare business Opella ... of over-the-counter medicines and dietary supplements and includes well-known brands like Allegra (fexofenadine) ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

On our radar 2024 BASF readies a massive restructuring Sanofi ... its consumer health business, Opella, to the US private equity firm Clayton, Dubilier & Rice (CD&R). Opella, which houses brands ...

Sanofi Consumer Health Care India Ltd, the pharmaceutical company that makes Combiflam among other consumer drugs, announced to sell 26% of its equity shares to Opal Bidco SAS along with U.S ...